Live feed09:00:00·4mPRReleasevia QuantisnowIMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian CancerByQuantisnow·Wall Street's wire, on your screen.IMNN· Imunon Inc.Health Care
